HopeStage
Back to all studies
RecruitingNCT05772104

Shugan Jieyu capsules or placebo for generalized anxiety

About this titleRead the official source — NCT05772104
Medication studyAges 18–65China
The study in practice

Understand this study

Who could participate?

This study is for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
BeijingSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: April 17, 2023
Recruitment status
Recruiting
Enrollment listed in the registry
495
Sponsor
Sichuan Jishengtang Pharmaceutical Co., Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
China
Age range
From 18 Years to 65 Years
Official registry ID
NCT05772104
Official title
Show the full official title

A Multi-center, Randomized, Double-Blind Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder

Recruitment & locations

Currently recruiting

Beijing

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Sichuan Jishengtang Pharmaceutical Co., Ltd., a pharmaceutical company.

Does this study involve medication?

Yes. The study involves medication, including Shugan Jieyu Capsules and Shugan Jieyu Capsules Placebo.

Who can participate?

This study is for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies